R. Ikeda

Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: interim analysis from a post-marketing surveillance study

K. Kaku, Yusuke Naito, A. Yasui, 2019, Expert opinion on drug safety.

Preferential prescribing of linagliptin in type 2 diabetes patients in an expanded post‐marketing surveillance study in Japan

D. Bartels, A. Taniguchi, K. Brodovicz, 2019, Journal of diabetes investigation.

Long-Term Safety and Effectiveness of Linagliptin in Japanese Patients with Type 2 Diabetes and Renal Dysfunction: a Post-Marketing Surveillance Study

N. Hayashi, T. Hirase, Tomo-o Okamura, 2020, Diabetes Therapy.

Study on Use of Antisecretory Drugs following Treatment with Calcium Channel Blockers among Non-elderly Patients in Community Pharmacies

J. Ishii, K. Nakashima, M. Wada, 2011 .

Long-Term Safety and Effectiveness of Linagliptin in Japanese Patients with Type 2 Diabetes Mellitus: A 3-Year Post-Marketing Surveillance Study

N. Hayashi, Tomo-o Okamura, Fumiko Yamamoto, 2019, Diabetes Therapy.

Influence of calcium channel blockers in patients with gastrointestinal disease in Japanese community pharmacies

J. Ishii, K. Nakashima, M. Wada, 2012, Journal of clinical pharmacy and therapeutics.

Real-world treatment of over 1600 Japanese patients with EGFR mutation-positive non-small cell lung cancer with daily afatinib

A. Gemma, Y. Nakanishi, T. Nukiwa, 2019, International Journal of Clinical Oncology.